0001402328 1 2026-10-01 2026-10-01 0001402328 2 2026-10-01 2026-10-01 0001402328 3 2026-10-01 2026-10-01 0001402328 4 2026-10-01 2026-10-01 0001402328 5 2026-10-01 2026-10-01 0001402328 6 2026-10-01 2026-10-01 0001402328 7 2026-10-01 2026-10-01 0001402328 2026-10-01 2026-10-01 iso4217:USD pure S-1 EX-FILING FEES 0001402328 N/A N/A S-1 Sunshine Biopharma Inc. false Equity Common Units, each consisting of: (i) one share of common stock, 0.001 par value per share (Common Stock) and (ii) two Series D Warrants to purchase shares of Common Stock true 7000000.00 0.000087 609.00 false Equity Common Stock included as part of the Common Units true 0.00 0.000087 0.00 false Other Pre-Funded Units, each consisting of: (i) one Pre-Funded Warrant exercisable for one share of Common Stock; and (ii) two Series D Warrants true 0.00 0.000087 0.00 false Other Pre-Funded Warrants to purchase Common Stock, included as part of the Pre-Funded Units true 0.00 0.000087 0.00 false Equity Common Stock underlying Pre-Funded Warrants true 0.00 0.000087 0.00 false Other Series D Warrants to Purchase Common Stock, included as part of the Common Units and Pre-Funded Units true 0.00 0.000087 0.00 false Equity Common Stock underlying Series D Warrants true 14000000.00 0.000087 1218.00 21000000.00 1827.00 0.00 1827.00 Estimated solely for the purpose of calculating the amount of the registration fee in accordance with Rule 457(o) under the Securities Act of 1933, as amended (the "Securities Act"). Pursuant to Rule 416 under the Securities Act, this registration statement shall also cover any additional shares of the registrant's securities that become issuable by reason of any share splits, share dividends or similar transactions. See footnote 1 The proposed maximum aggregate offering price of Common Units proposed to be sold in the offering will be reduced on a dollar-for-dollar basis based on the offering price of any Pre-Funded Units sold in the offering, and the proposed maximum aggregate offering price of the Pre-Funded Units to be sold in the offering will be reduced on a dollar-for-dollar basis based on the offering price of any Common Units sold in the offering. Accordingly, the proposed maximum aggregate offering price of the Common Units and Pre-Funded Units is $7,000,000. No separate registration fee is payable pursuant to Rule 457(g) under the Securities Act. See footnote 1 See footnote 1 The exercise price of each Series D Warrant is equal to the offering price per Common Unit.